MPM Capital
MPM Capital is a biotechnology investment firm that invests in early-stage companies to develop therapeutic technologies in oncology.
Business Model:
Revenue: $4.5M
Employees: 11-50
Rankings
Industries / Tags:
Detailed MPM Capital Information
Geographic Data
Address: 450 Kendall Street
City: Cambridge
State: MA
Zip: 02142
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$2B
Social
Twitter
Linkedin
Crunchbase
Metrics
966,501Website Global Rank
28,580Website Monthly Traffic
Twitter Followers
Description
MPM Capital is a healthcare investment firm that invests in early-stage companies developing therapeutic technologies in oncology. They invest in life sciences companies that seek to cure diseases by translating science into clinical outcomes. They prefer to invest in the biotechnology, healthcare, and life sciences sectors.
Contact Phone:
+16174259200
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2011 | Meritage Pharma | Venture Round | 6.5M |
| 5/2008 | SAI Life Sciences | Private Equity Round | 20M |
| 7/2009 | iPierian | Venture Round | 11.5M |
| 4/2016 | Twentyeight-Seven Therapeutics | Series A | - |
| 8/2008 | Peplin | Private Equity Round | 24M |
| 7/2005 | Integrated Diagnostics | Series A | - |
| 5/2003 | Acorda Therapeutics | Series B | 55.3M |
| 11/2017 | Semma Therapeutics | Series B | 0 |
| 11/2006 | Elixir Pharmaceuticals | Series C | 0 |
| 12/2018 | Entrada Therapeutics | Series A | 59M |
| 10/2003 | Elixir Pharmaceuticals | Series B | 40.5M |
| 1/2020 | BioIntervene | Series A | 30M |
| 3/2020 | ElevateBio | Series B | 170M |
| 11/2004 | Accelerator Corp. | Venture Round | 0 |
| 6/2005 | Amphora Discovery | Series D | 9.6M |
| 10/2009 | Xanodyne | Venture Round | 0 |
| 2/2008 | Epizyme | Series A | - |
| 7/2008 | Peptimmune | Series D | 8.9M |
| 4/2002 | IntraLuminal Therapeutics | Venture Round | 20M |
| 11/2020 | Umoja Biopharma | Series A | 53M |
| 7/2002 | ARYx Therapeutics | Series C | 25M |
| 5/2003 | Quantum Dot | Series B | 1.5M |
| 2/2015 | Chiasma | Series E | 70M |
| 9/2019 | Repare Therapeutics | Series B | 82.5M |
| 2/2000 | DoubleTwist | Series D | 37M |
| 1/2012 | Kalidex Pharmaceuticals | Venture Round | 6.5M |
| 6/2002 | MacroGenics | Venture Round | 12.6M |
| 6/2004 | ARYx Therapeutics | Series D | 55M |
| 7/2005 | Affymax | Series D | 60M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 11.4M |
| 11/2006 | Chiasma | Series C | 44M |
| 12/2020 | Cullinan Oncology | Series C | 131.2M |
| 8/2022 | Orna Therapeutics | Series B | 0 |
| 6/2019 | Frontier Medicines | Series A | 67M |
| 6/2012 | Motus Therapeutics | Series B | 25M |
| 8/2005 | Innovative Spinal Technologies | Series B | 39M |
| 5/2005 | Cellerant Therapeutics | Series B | 16M |
| 7/2011 | Verastem Oncology | Series B | 32M |
| 1/2002 | BioXell | Series A | 19.7M |
| 4/2020 | ITeos Therapeutics | Series B | 0 |
| 12/2016 | TCR2 | Series A | 44.5M |
| 9/2010 | EnteroMedics | Post-IPO Equity | 6.3M |
| 11/2008 | Pacira Pharmaceuticals | Series A | 85M |
| 3/2020 | ReCode Therapeutics | Series A | 0 |
| 3/2010 | Motus Therapeutics | Series A | 21M |
| 9/2011 | Valeritas | Series C | 150M |
| 3/2008 | EKR Therapeutics | Series D | 50M |
| 4/2007 | Radius Health | Series B | 57.5M |
| 9/2007 | JapanBridge | Series A | 6.5M |
| 4/2019 | Dyne Therapeutics | Series A | 50M |
| 1/2020 | Orna Therapeutics | Seed Round | 20M |
| 12/2006 | NBI Development | Seed Round | 5.5M |
| 3/2015 | Clinical Ink | Venture Round | 20M |
| 9/2019 | Amphivena Therapeutics | Series C | 0 |
| 12/2002 | Intracel Holdings Corporation | Series B | 16M |
| 3/2006 | Neuromed Pharmaceuticals | Series D | 0 |
| 4/2015 | True North Therapeutics | Series B | 35M |
| 1/2011 | Aratana Therapeutics | Series A | 0 |
| 8/2015 | Syndax Pharmaceuticals | Series C | 0 |
| 4/2011 | Conatus Pharmaceuticals | Series B | 7.5M |
| 12/2021 | CODA Biotherapeutics | Venture Round | 0 |
| 10/2003 | Cotherix | Series C | 55M |
| 6/2006 | VLST Corporation | Series B | 55M |
| 10/2003 | Critical Therapeutics,Inc. | Series B | 56M |
| 3/2021 | Entrada Therapeutics | Series B | 0 |
| 6/2017 | Repare Therapeutics | Series A | 68M |
| 2/2006 | Amphora Discovery | Series E | 4.4M |
| 12/2012 | 23andMe | Series D | 50M |
| 9/2011 | Theraclone Sciences | Series B | 10.6M |
| 7/2016 | Oncorus | Series A | 57M |
| 1/2008 | PrimeraDx (Primera Biosystems) | Series B | 21M |
| 11/2012 | Motus Therapeutics | Series B | 8M |
| 3/2009 | Surface Logix | Series E | 15M |
| 3/2008 | TriVascular | Series A | 65M |
| 7/2009 | Somaxon Pharmaceuticals | Post-IPO Equity | 6M |
| 8/2010 | EndoGastric Solutions | Series F | 0 |
| 3/2015 | Vascular Pharmaceuticals | Series A | 9M |
| 5/2023 | ReNAgade Therapeutics | Series A | 0 |
| 6/2009 | EndoGastric Solutions | Venture Round | 3.8M |
| 8/2001 | Eyetech Pharmaceuticals | Series C | 108.5M |
| 11/2019 | Werewolf Therapeutics | Series A | 0 |
| 6/2003 | Xoft | Series B | 0 |
| 10/2014 | Raze Therapeutics | Series A | 24M |
| 4/2003 | Epigenomics | Series C | 22.5M |
| 5/2007 | Portola Pharmaceuticals | Series C | 70M |
| 3/2005 | Humanigen | Series B | 20M |
| 6/2003 | EndoGastric Solutions | Series A | 5M |
| 4/2003 | Rigel Pharmaceuticals | Post-IPO Equity | 46M |
| 1/2009 | TaiGen Biotechnology | Series C | 0 |
| 3/2004 | TaiGen Biotechnology | Series B | 0 |
| 7/2009 | PharmAthene | Post-IPO Secondary | 19.3M |
| 6/2007 | Ceregene | Series C | 0 |
| 7/2011 | Radius Health | Series C | 66M |
| 5/2017 | Harpoon Therapeutics | Series B | 45M |
| 9/2004 | EndoGastric Solutions | Series B | 12M |
| 3/2013 | CoStim Pharmaceuticals | Series A | 22M |
| 11/2006 | Orexigen Therapeutics, Inc. | Series C | 30M |
| 12/2011 | Aratana Therapeutics | Series B | 15M |
| 3/2007 | Theraclone Sciences | Series B | 29M |
| 8/2003 | Rinat Neuroscience | Series B | 40M |
| 9/2008 | Humanigen | Series D | 0 |
| 11/2019 | CODA Biotherapeutics | Series A | 15M |
| 5/2007 | QuatRx Pharmaceuticals | Series E | 0 |
| 7/2011 | Nevro | Series B | 58M |
| 12/2011 | Radius Health | Private Equity Round | 21.4M |
| 10/2009 | PrimeraDx (Primera Biosystems) | Series C | 20M |
| 10/2009 | Epizyme | Series B | 32M |
| 4/2014 | Iconic Therapeutics | Series B | 20M |
| 6/2012 | TriVascular | Series D | 60M |
| 3/2018 | TCR2 | Series B | 0 |
| 3/2010 | Rhythm Pharmaceuticals | Series A | 40M |
| 5/2003 | Accelerator Corp. | Venture Round | 0 |
| 7/2005 | Peptimmune | Series C | 20.4M |
| 10/2013 | Sideris Pharmaceuticals | Series A | 32M |
| 11/2010 | Aires Pharmaceuticals | Series B | 20M |
| 3/2009 | NeoVista | Series D | 18M |
| 5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
| 12/2005 | Hypnion | Series B | 0 |
| 7/2014 | Valeritas | Series D | 45M |
| 4/1999 | Omrix Biopharmaceuticals | Venture Round | 20M |
| 11/2019 | SiO2 Materials Science | Venture Round | - |
| 8/2004 | Pharmasset | Series D | 40M |
| 9/2022 | Photys | Series A | 0 |
| 8/2022 | Aktis Oncology | Series A | 0 |
| 10/2021 | ReCode Therapeutics | Series B | 0 |
| 10/2021 | Protego Biopharma | Series A | 0 |
| 5/2023 | ElevateBio | Series D | 0 |
| 11/2008 | Radius Health | Series C | 15M |
| 4/2007 | Xoft | Series D | 0 |
| 4/2007 | Syndax Pharmaceuticals | Series A | 40M |
| 3/2010 | Syndax Pharmaceuticals | Series A | 9M |
| 8/2013 | Syndax Pharmaceuticals | Series B | 0 |
| 5/2005 | Xoft | Series C | 0 |
| 6/2018 | Iconic Therapeutics | Venture Round | 0 |
| 7/2005 | PrimeraDx (Primera Biosystems) | Series A | 11M |
| 6/2012 | Astute Medical | Series C | 40.4M |
| 1/2016 | Tizona Therapeutics | Series A | 27M |
| 9/1999 | Pointshare | Series C | 40M |
| 11/2000 | Epigenomics | Venture Round | 24.1M |
| 7/2003 | Tercica | Series B | 44M |
| 5/2012 | Celladon | Venture Round | 10M |
| 5/2003 | BioXell | Series B | 19.9M |
| 10/2007 | Allozyne | Series B | 30M |
| 7/2013 | InformedDNA | Seed Round | 3M |
| 12/2005 | Allozyne | Series A | 3.5M |
| 3/2013 | Theraclone Sciences | Series B | 0 |
| 5/2009 | Elixir Pharmaceuticals | Series D | 12M |
| 3/2010 | Theraclone Sciences | Venture Round | 1.5M |
| 9/2012 | Selexys Pharmaceuticals Corporation | Series A | 23M |
| 10/2004 | MacroGenics | Series B | 30.5M |
| 3/2016 | Potenza Therapeutics | Venture Round | 30M |
| 9/2008 | ForteBio | Series C | 25M |
| 5/2006 | MacroGenics | Series C | 45M |
| 9/2001 | MacroGenics | Series A | 13.5M |
| 4/2007 | Cellerant Therapeutics | Series B | 0 |
| 6/2004 | Idun Pharmaceuticals | Venture Round | 0 |
| 4/2001 | Genteric | Series B | 22M |
| 1/2023 | NextPoint Therapeutics | Series B | 0 |
| 12/2006 | Nevro | Seed Round | 5.5M |
| 9/2008 | Nevro | Series A | 21.8M |
| 4/2018 | Tetherex | Series B | 50M |
| 1/2010 | Alnara Pharmaceuticals | Series B | 35M |
| 11/2003 | Neuromed Pharmaceuticals | Series C | 32M |
| 8/2007 | Neuromed Pharmaceuticals | Series E | 0 |
| 3/2004 | Cardiac Dimensions | Series C | 15M |
| 1/2016 | Iconic Therapeutics | Series C | 40M |
| 3/2021 | ElevateBio | Series C | 525M |
| 8/2016 | Iconic Therapeutics | Series C | 10M |
| 6/2020 | Cullinan Oncology | Series B | 98.5M |
| 10/2017 | Cullinan Oncology | Series A | 150M |
| 9/2010 | Motus Therapeutics | Series A | 19M |
| 6/2018 | ITeos Therapeutics | Series B | 0 |
| 8/2003 | Archus Orthopedics | Series B | 18M |
| 2/2012 | Helicos BioSciences | Series A | 27M |
| 1/2004 | CGI Pharmaceuticals | Series C | 22.3M |
| 12/2003 | Portola Pharmaceuticals | Series A | 21M |
| 11/2005 | Portola Pharmaceuticals | Series B | 46M |
| 7/2008 | Portola Pharmaceuticals | Series C | 60.1M |
| 3/2021 | Aktis Oncology | Series A | 72M |
| 3/2001 | Pharmasset | Series C | 7.4M |
| 7/2003 | Intercell | Series C | 50M |
| 10/2014 | Atopix Therapeutics | Series A | 0 |
| 11/2011 | Verastem Oncology | Series C | 20M |
| 10/2005 | Cerimon Pharmaceuticals | Series A | 70M |
| 5/2002 | AVEO Oncology | Series A | 15M |
| 3/2003 | Peptimmune | Series B | 41.2M |
| 2/2011 | NeoVista | Series E | 33M |
| 12/2004 | Amphora Discovery | Series C | 20M |
| 2/2017 | Rhythm Pharmaceuticals | Venture Round | 41M |
| 11/2009 | Oxagen | Series C | 0 |
| 5/2009 | Proteon Therapeutics | Series B | 50M |
| 10/2007 | Acceleron Pharma | Series C | 31M |
| 6/2006 | Peptimmune | Series C | 0 |
| 8/2015 | Rhythm Metabolic | Series A | 40M |
| 8/2010 | TriVascular | Series C | 60M |
| 11/2009 | TriVascular | Series B | 30M |
| 3/2013 | Nevro | Series C | 0 |
| 10/2003 | AVEO Oncology | Series B | 42.7M |
| 10/2004 | BioXell | Series C | 29M |
| 4/2004 | Corus Pharma | Series C | 0 |
| 8/2020 | Dyne Therapeutics | Series B | 115M |
| 9/2012 | Vascular Pharmaceuticals | Series A | 16M |
| 5/2010 | Ntprx | Series B | 43M |
| 9/2016 | IOmx Therapeutics | Series A | 44.6M |
| 11/2010 | iPierian | Series B | 29M |
| 9/2013 | iPierian | Venture Round | 30M |
| 12/2015 | True North Therapeutics | Series C | 40M |
| 8/2019 | Oncorus | Series B | 0 |
| 6/2016 | Blade Therapeutics | Series B | 45M |
| 5/2014 | Proteon Therapeutics | Series D | 0 |
| 11/2013 | TriVascular | Series E | 0 |
| 11/2018 | Harpoon Therapeutics | Series C | 70M |
| 8/2000 | Syrrx | Series A | 5.1M |
| 7/2015 | Blade Therapeutics | Series A | 6.5M |
| 1/2010 | Dragonfly Sciences | Venture Round | - |
| 1/2005 | CHF Solutions | Venture Round | 22.9M |
| 3/2019 | TriNetX | Series D | 40M |
| 1/2002 | CryoCor | Series B | 12M |
| 11/2009 | EndoGastric Solutions | Series E | 0 |
| 10/2009 | EndoGastric Solutions | Venture Round | 0 |
| 2/2003 | Synergia Pharma | Series A | 2M |
| 11/2006 | Solasia Pharma | Pre Seed Round | - |
| 5/2015 | Blade Therapeutics | Seed Round | - |
| 12/2006 | NeoVista | Series C | 41M |
| 9/2018 | CODA Biotherapeutics | Series A | 19M |
| 6/2002 | Cardiac Dimensions | Series B | 12M |
| 6/2013 | Pierian Biosciences | Private Equity Round | 18M |
| 1/2002 | Archus Orthopedics | Series A | - |
| 8/2011 | Proteon Therapeutics | Series C | 15.2M |
| 6/2007 | Athersys | Venture Round | 0 |
| 1/2011 | Mitobridge | Seed Round | - |
| 7/2021 | Frontier Medicines | Series B | 0 |
| 3/2003 | Hypnion | Series B | 47.5M |
| 1/2021 | Werewolf Therapeutics | Series B | 0 |
| 12/2007 | Cardiac Dimensions | Series D | 0 |
| 3/2004 | Restore Medical | Series C | 26.5M |
| 12/2008 | Humanigen | Series D | 12M |
| 12/2019 | Triplet Therapeutics | Series A | 49M |
| 10/2004 | PharmAthene | Series B | 50M |
| 11/2008 | ARYx Therapeutics | Post-IPO Equity | 21.6M |
| 1/2008 | Peptimmune | Series D | 8.2M |
| 1/2012 | CoStim Pharmaceuticals | Seed Round | - |
| 6/2014 | True North Therapeutics | Series A | 22M |
| 7/2007 | Xanodyne | Series A | 25M |
| 4/2004 | Affymax | Series C | 20M |
| 10/1999 | Pharmasset | Series B | 3.9M |
| 5/2003 | Cellerant Therapeutics | Series A | 10M |
| 6/2005 | Verus Pharmaceuticals | Series A | 0 |
| 7/2014 | Cerecor | Series B | 32M |
| 10/2015 | 23andMe | Series E | 115M |
| 5/2001 | SenoRx | Venture Round | 19M |
| 6/2003 | CryoCor | Series C | 27.5M |
| 10/2005 | Alinea Pharmaceuticals | Series A | 45M |
| 11/2002 | Critical Therapeutics,Inc. | Series A | 10M |
| 9/2008 | Valeritas | Series A | 50M |
| 9/2008 | Innovative Spinal Technologies | Series C | 18M |
| 1/2006 | Xoft | Series C | 0 |
| 9/2000 | CryoCor | Series A | 7M |
| 7/2004 | Arriva Pharmaceuticals | Series D | - |
| 8/2004 | Ceregene | Series B | 32M |
| 2/2006 | NeoRX Corporation (Poniard Pharmaceuticals) | Post-IPO Equity | 65M |
| 1/2011 | 23andMe | Series C | 9M |
| 11/2004 | Neosil | Series A | 32M |
| 3/2016 | Tizona Therapeutics | Series B | 43M |
| 3/2006 | Helicos BioSciences | Series B | 40M |
| 3/2017 | Semma Therapeutics | Venture Round | - |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 14M |
| 5/2005 | Oxagen | Series B | 0 |
| 1/2017 | Maverick Therapeutics | Venture Round | 125M |
| 1/2013 | Aratana Therapeutics | Series C | 0 |
| 6/2016 | arGEN-X | Post-IPO Equity | 34.1M |
| 11/2010 | Verastem Oncology | Series A | 16M |
| 2/2006 | ARYx Therapeutics | Series E | 30.4M |
| 7/2012 | Chiasma | Series D | 38.5M |
| 1/2004 | Amphora Discovery | Series B | 12.9M |
| 3/2015 | Semma Therapeutics | Series A | 44M |
| 7/2005 | Xanodyne | Series A | 170M |
| 6/2005 | Somaxon Pharmaceuticals | Series C | 0 |
| 2/2021 | Orna Therapeutics | Series A | 0 |
| 10/2013 | Mitobridge | Series A | 0 |
| 9/2018 | Twentyeight-Seven Therapeutics | Series A | 65M |
| 8/2020 | Trishula Therapeutics | Funding Round | - |
| 4/2013 | Radius Health | Private Equity Round | 43M |
| 1/2006 | Archus Orthopedics | Series C | 35M |
| 12/2002 | Amphora Discovery | Series B | 12.5M |
| 4/2016 | Harpoon Therapeutics | Series A | 15M |
| 5/2012 | NeoVista | Venture Round | 6M |
| 5/2023 | ReNAgade Therapeutics | Series A | 0 |
| 1/2023 | NextPoint Therapeutics | Series B | 0 |
| 9/2022 | Photys Therapeutics | Series A | 0 |
| 8/2022 | Aktis Oncology | Series A | 0 |
| 8/2022 | Orna Therapeutics | Series B | 0 |
| 12/2021 | CODA Biotherapeutics | Venture Round | 0 |
| 10/2021 | ReCode Therapeutics | Series B | 0 |
| 10/2021 | Protego Biopharma | Series A | 0 |
| 7/2021 | Frontier Medicines | Series B | 0 |
| 3/2021 | Entrada Therapeutics | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
